This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday
Avi Kapoor 5 months ago
NewsDowngradesMarketsAnalyst RatingsTrading Ideas
Analysts changed outlook on top names, including SMMT, DAVA. See what others think before buying SMMT stock.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- HC Wainwright & Co. analyst Mitchell S. Kapoor downgraded Summit Therapeutics Inc (NASDAQ:SMMT) from Buy to Neutral. Summit Therapeutics shares closed at $17.47 on Thursday. See how other analysts view this stock.
- JP Morgan analyst Puneet Jain downgraded Endava PLC – ADR (NYSE:DAVA) from Neutral to Underweight and lowered the price target from $9 to $5. Endava shares closed at $3.34 on Thursday. See how other analysts view this stock.
Considering buying SMMT stock? Here’s what analysts think:
Photo via Shutterstock